MENS

New Taipei City, Taiwan/San Francisco, CA, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it will hold a two-day investor events on Saturday, October 24, 2026 in Mountain View, California in Silicon Valley and on Sunday, October 25, 2026 in Irvine, California. The meetings will be conducted in person, with management set to discuss the Company’s recent operational highlights and strategic growth initiatives. Event Registration Saturday, October 24, 2026, from 4:30 PM to 7:30 PM PT i

New Taipei City, Taiwan, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it plans to establish a potential new manufacturing facility and U.S. operations center in Texas. The initiative is intended to support the Company’s U.S. operations and position it for the potential future commercialization of its proprietary investigational drug candidates, if approved. Following an evaluation of factors including government policies, market conditions, workforce recruitment and logistics, Jyon

New Taipei City, Taiwan/San Francisco, CA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced it will participate in StockFan Virtual Investor Non-Deal Roadshow on Sunday, September 6, 2026 (U.S. Eastern Time) / Monday, September 7, 2026 (Taipei Time). Event Schedule The virtual event will be conducted in both Mandarin Chinese and English, accessible across multiple time zones to accommodate the Company’s global investor base: New York (EDT): Sunday, September 6, 2026, from 8:30 PM to 9:30

New Taipei City, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today reaffirmed its strategic focus on pursuing global licensing partnerships to address the growing medical needs in the urology sector. Building upon the momentum of its recent participation at the BIO 2026 International Convention, the Company continues to actively engage in discussions with international pharmaceutical companies and industry partners across multiple regions, aiming to continuously expand its global cooperation n

New Taipei City, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced its participation in the BIO International Convention (BIO 2026), held in San Diego, California, from June 22 to June 25, 2026. Having participated in the BIO International Convention for over a decade without missing a single year, Jyong Biotech once again exhibited at the Taiwan Pavilion. The Company conducted in-depth discussions with global pharmaceutical companies, investment institutions, and industry partners an

New Taipei City, Taiwan, May 29, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today highlighted a strategic vision detailed by its founder and chief executive officer, Ms. Fu-Feng Kuo, in a recently published live interview with PharmaBoardroom, a UK-based platform providing global intelligence for the healthcare and life sciences industries. In the interview, CEO Kuo described how Jyong Biotech has built its scientific foundation through a hybrid operating model, pairing its Taiwanese R&D subsidiary, Health Ev

New Taipei City, Taiwan, May 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission ("SEC") on May 14, 2026. The annual report can be accessed on the Company's investor relations website at https://jyongir.com/ as well as the SEC's website at http://www.sec.gov.  The Company will provide a hard copy of annual report containing the audited consolidated financial sta

20-F - Jyong Biotech Ltd. (0001954488) (Filer)

NT 20-F - Jyong Biotech Ltd. (0001954488) (Filer)

3 - Jyong Biotech Ltd. (0001954488) (Issuer)

3 - Jyong Biotech Ltd. (0001954488) (Issuer)

3 - Jyong Biotech Ltd. (0001954488) (Issuer)

3 - Jyong Biotech Ltd. (0001954488) (Issuer)

3 - Jyong Biotech Ltd. (0001954488) (Issuer)

3 - Jyong Biotech Ltd. (0001954488) (Issuer)

3 - Jyong Biotech Ltd. (0001954488) (Issuer)

New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today provided an update on the plant-derived innovative drug MCS®-2 of its multiple competitive advantages and its potential clinical benefits in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS). Pioneering Plant-Based TherapeuticsDeveloped in Taiwan, MCS®-2 is the world's only oral botanical new drug to have completed a global Phase III clinical trial for benign prostatic hyperplasia (BPH). Jyo

- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial partnerships in South Korea and Vietnam.New Taipei City, Taiwan, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today issued a strategic corporate update. This review encapsulates a pivotal period characterized by the successful completion of the Phase II clinical trial for its lead candidate, MCS

6-K - Jyong Biotech Ltd. (0001954488) (Filer)

New Taipei City, Taiwan, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced updated statistical analyses for key blood biochemical markers from its Phase II clinical trial of MCS-8 (PCP) conducted in Taiwan. The results underscore MCS-8's previously indicated multifaceted clinical and commercial potential beyond its clinical evidence in pros

6-K - Jyong Biotech Ltd. (0001954488) (Filer)

New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech") notes the recent fluctuation in its share price and the increased trading volume of its shares on the Nasdaq Stock Exchange following the expiry of the lock-up period this month. The Company has been in ongoing discussions with certain investment funds that are interested in purchasing the Company's ordinary shares. The Company confirms that it is in compliance with its continuous disclosure obligations under the SEC regulations. The Company is not aware of any material, unpublished price-sensitive information or corporate developments that would explain the recen

New Taipei City, Taiwan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that it has entered into a non-binding Memorandum of Understanding (the "MOU") with a Vietnam‑based pharmaceutical distribution company headquartered in Ho Chi Minh City, to evaluate the development and commercialization of MCS‑2 in the Vietnam pharmaceutical market.

New Taipei City, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that the Company has entered into a non‑binding letter of intent (the "LOI") with a South Korean pharmaceutical company to review and evaluate the potential in‑licensing and development of Jyong Biotech's plant-derived new drug MCS-2for the Korean market. The prospec

New Taipei City, Taiwan, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that it has achieved another milestone in the development of its plant-derived new drug MCS-8 (PCP). The Company has completed the statistical analysis of the primary efficacy endpoints in its ongoing Phase II clinical trial conducted in Taiwan, following the random